Skip to content

Zynerba rated buy, target $25, by Roth

March 18, 2017

Roth Capital set a $25.00 price objective on Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) in a report published on Tuesday morning. The firm currently has a buy rating on the stock.

http://bit.ly/2nCPiAu

Advertisements

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: